IL107003A0 - 3,3'-disubstituted-1,3-dihydro-2h-pyrrolo(2,3,-b)heterocyclic-2-one useful in the treatment of cognitive disorders of man - Google Patents

3,3'-disubstituted-1,3-dihydro-2h-pyrrolo(2,3,-b)heterocyclic-2-one useful in the treatment of cognitive disorders of man

Info

Publication number
IL107003A0
IL107003A0 IL107003A IL10700393A IL107003A0 IL 107003 A0 IL107003 A0 IL 107003A0 IL 107003 A IL107003 A IL 107003A IL 10700393 A IL10700393 A IL 10700393A IL 107003 A0 IL107003 A0 IL 107003A0
Authority
IL
Israel
Prior art keywords
pyrrolo
disubstituted
dihydro
heterocyclic
man
Prior art date
Application number
IL107003A
Other languages
English (en)
Original Assignee
Du Pont Merck Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Merck Pharma filed Critical Du Pont Merck Pharma
Publication of IL107003A0 publication Critical patent/IL107003A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IL107003A 1992-09-18 1993-09-14 3,3'-disubstituted-1,3-dihydro-2h-pyrrolo(2,3,-b)heterocyclic-2-one useful in the treatment of cognitive disorders of man IL107003A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/947,152 US5278162A (en) 1992-09-18 1992-09-18 3,3'-disubstituted-1,3-dihydro-2H-pyrrolo[2,3-b]heterocyclic-2-one useful in the treatment of cognitive disorders of man

Publications (1)

Publication Number Publication Date
IL107003A0 true IL107003A0 (en) 1993-12-28

Family

ID=25485622

Family Applications (1)

Application Number Title Priority Date Filing Date
IL107003A IL107003A0 (en) 1992-09-18 1993-09-14 3,3'-disubstituted-1,3-dihydro-2h-pyrrolo(2,3,-b)heterocyclic-2-one useful in the treatment of cognitive disorders of man

Country Status (10)

Country Link
US (1) US5278162A (OSRAM)
EP (1) EP0660833A1 (OSRAM)
JP (1) JPH08501550A (OSRAM)
CN (1) CN1094406A (OSRAM)
AU (1) AU4856893A (OSRAM)
CA (1) CA2144636A1 (OSRAM)
IL (1) IL107003A0 (OSRAM)
TW (1) TW248560B (OSRAM)
WO (1) WO1994006793A1 (OSRAM)
ZA (1) ZA936872B (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5296478A (en) * 1992-10-07 1994-03-22 The Dupont Merck Pharmaceutical Co. 1-substituted oxindoles as cognition enhancers
PT757685E (pt) 1994-04-29 2004-10-29 Pfizer Novas amidas ciclicas como incrementadores de libertacao de neurotransmissores
US5744476A (en) * 1994-06-27 1998-04-28 Interneuron Pharmaceuticals, Inc. Dopamine D1 agonists for the treatment of dementia
MY145694A (en) * 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
MY144968A (en) * 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AR053713A1 (es) * 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
ATE545416T1 (de) * 2006-10-12 2012-03-15 Xenon Pharmaceuticals Inc Verwendung von spiro-oxindol-verbindungen als therapeutika
CL2007002953A1 (es) * 2006-10-12 2008-02-01 Xenon Pharmaceuticals Inc Compuestos derivados de espiro-oxindol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del dolor, cancer, prurito, hiperplasia prostatica benigna, hipercolesterolemia.
EP2076518A1 (en) * 2006-10-12 2009-07-08 Xenon Pharmaceuticals Inc. Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents
CA2741024A1 (en) * 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
BRPI0920448A2 (pt) * 2008-10-17 2018-10-23 Xenon Pharmaceuticals Inc. compostos spiro-oxindol e seu uso como agentes terapêuticos
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
WO2011047173A2 (en) * 2009-10-14 2011-04-21 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
RU2544852C2 (ru) 2009-10-14 2015-03-20 Ксенон Фармасьютикалз Инк. Способы синтеза спиро-оксиндольных соединений
PE20121699A1 (es) 2010-02-26 2012-12-22 Xenon Pharmaceuticals Inc Composiciones farmaceuticas del compuesto espiro-oxindol para administracion topica
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760083A (en) * 1986-04-10 1988-07-26 E. I. Dupont De Nemours & Company 3,3-disubstituted indolines
GB8714371D0 (en) * 1987-06-19 1987-07-22 Smith Kline French Lab Process
AU3776589A (en) * 1988-06-14 1990-01-12 Schering Corporation Heterobicyclic compounds having antiinflammatory activity
US5006537A (en) * 1989-08-02 1991-04-09 Hoechst-Roussel Pharmaceuticals, Inc. 1,3-dihydro-1-(pyridinylamino)-2H-indol-2-ones

Also Published As

Publication number Publication date
AU4856893A (en) 1994-04-12
ZA936872B (en) 1995-03-17
EP0660833A1 (en) 1995-07-05
WO1994006793A1 (en) 1994-03-31
TW248560B (OSRAM) 1995-06-01
JPH08501550A (ja) 1996-02-20
US5278162A (en) 1994-01-11
CA2144636A1 (en) 1994-03-31
CN1094406A (zh) 1994-11-02

Similar Documents

Publication Publication Date Title
GB9215633D0 (en) Novel treatment
IL110204A0 (en) Novel indolene derivatives, processes for their preparation and their use for the treatment of cns disorders
IL107003A0 (en) 3,3'-disubstituted-1,3-dihydro-2h-pyrrolo(2,3,-b)heterocyclic-2-one useful in the treatment of cognitive disorders of man
ZA904991B (en) 5,11-dihydro-6h-dipyrido(3,2-b:2',3'-e)(1,4)-diazepin-6-ones and-thiones and their use for the treatment of aids
GB9226860D0 (en) Novel treatment
FI943765A7 (fi) 4-aminopyridiinin käyttö neurologisen tilan hoidossa
KR970000398B1 (en) Process for the preparation of 1,1,1,2-tetrafluoro-2-chloroethan and pentafluorethane
GB9203039D0 (en) Treatment
ZA935154B (en) Use of 1,2,5-oxadiazole-2-oxides for the treatment of erectile dysfunctions
GB9201920D0 (en) Novel treatment i
ZA931063B (en) Treatment of glaucoma.
EP0557949A3 (en) Process for the preparation of 2,4,5 trifluorobenzonitrile
GB9222985D0 (en) Use of the tarchonanthus camphoratus
AP9300527A0 (en) Novel treatment
GB9214373D0 (en) Newadjustable "photo-back"
GB2282529B (en) Baby's bath
GB9225859D0 (en) Novel treatment
GB9203637D0 (en) Novel treatment
ZA936874B (en) Process for the preparation of 5,6-diacetoxyindole
ZA937604B (en) 3,3-disubstituted tri and tetracyclic indolin-2-ones useful for the treatment of cognitive disorders
EP0579077A3 (en) 1,3,4-thiadiazinones for the treatment of cardiovascular diseases
GB9607420D0 (en) Formulations of mannose phosphates useful in the treatment of fibrotic disorders
IL100629A0 (en) Apparatus for the treatment of papulosquamous disorders
GB9204036D0 (en) The"secura-grip"
GB9220588D0 (en) The "trailersafe"